BENITEC BIOPHAR/S (BNTC) Reaches New 1-Year Low at $1.78
BENITEC BIOPHAR/S (NASDAQ:BNTC)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $1.78 and last traded at $1.78, with a volume of 6775 shares traded. The stock had previously closed at $1.92.
An institutional investor recently bought a new position in BENITEC BIOPHAR/S stock. Sphera Funds Management LTD. acquired a new position in BENITEC BIOPHAR/S (NASDAQ:BNTC) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 120,000 shares of the biotechnology company’s stock, valued at approximately $294,000. Sphera Funds Management LTD. owned approximately 1.09% of BENITEC BIOPHAR/S as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 4.67% of the company’s stock.
BENITEC BIOPHAR/S Company Profile (NASDAQ:BNTC)
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B.
Further Reading: What is the Federal Reserve?
Receive News & Ratings for BENITEC BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BENITEC BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.